false 0001314102 0001314102 2021-11-13 2021-11-13

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): November 13, 2021

 

EyePoint Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Charter)

 

 

Delaware		000-51122		26-2774444
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

 

480 Pleasant Street

Watertown, MA 02472

(Address of Principal Executive Offices, and Zip Code)

(617) 926-5000

Registrant’s Telephone Number, Including Area Code

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐

Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001		EYPT		The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

---

 

 

Item 8.01. Other Events.

 

On November 13, 2021, EyePoint Pharmaceuticals, Inc. issued a press release announcing its reporting of positive interim safety and efficacy data from Phase 1 DAVIO clinical trial evaluating EYP-1901 for the treatment of wet age-related macular degeneration (“wet AMD”). A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.

 

On the same date, EyePoint Pharmaceuticals, Inc. posted EYP-1901 Phase 1 DAVIO study interim results presentation on its website at www.eyepointpharma.com. A copy of the presentation is filed herewith as Exhibit 99.2 and is incorporated by reference herein.

 

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit No.		Description
99.1		Press Release of EyePoint Pharmaceuticals, Inc., dated November 13, 2021
99.2		EYP-1901 Phase 1 DAVIO Study Interim Results Presentation of EyePoint Pharmaceuticals, Inc., dated November 13, 2021
104		Cover Page Interactive Data File (embedded within the inline XBRL document)

 

 

---

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

		EyePoint Pharmaceuticals, Inc.
Date: November 15, 2021		By:		/s/ George O. Elston
		Name:		George O. Elston
		Title		Chief Financial Officer and Head of Corporate Development

 

 

 

 

Exhibit 99.1

 

EyePoint Pharmaceuticals Reports Positive Interim Safety and Efficacy Data from Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD

 

 

WATERTOWN, Mass., November 13, 2021 – EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced six-month interim data from the “Durasert^® and Vorolanib in Ophthalmology” (DAVIO) Phase 1 clinical trial of EYP-1901, a bioerodible sustained delivery intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment targeting wet age-related macular degeneration (wet AMD). The data are being presented today at the American Academy of Ophthalmology (AAO) 2021 Annual Meeting Retina Subspecialty Day in New Orleans by David S. Boyer, M.D., Senior Partner at Retina-Vitreous Associates Medical Group and adjunct clinical professor of Ophthalmology with the University of Southern California/Keck School of Medicine.

“We are very encouraged by these data that reinforce EYP-1901’s positive safety profile and its durable anti-VEGF activity up to six months so far in the majority of enrolled patients after a single intravitreal injection,” said Nancy Lurker, Chief Executive Officer of EyePoint Pharmaceuticals. “Wet AMD is a leading cause of blindness, and these data bring us one step closer to potentially changing the standard of care for patients by offering an in-office sustained delivery treatment option with the potential for up to every six-month dosing.”

The Phase 1 DAVIO clinical trial is an open-label, dose escalation clinical trial of EYP-1901 that enrolled 17 patients with previously treated wet AMD. EYP-1901 is a sustained delivery anti-VEGF (voralanib) investigational treatment that utilizes a bioerodible formulation of EyePoint’s Durasert^® drug delivery technology that has been utilized in four FDA-approved products, including EyePoint’s YUTIQ^® for chronic non-infectious uveitis affecting the posterior segment of the eye.  

 

---

 

Six-month interim data from the Phase 1 DAVIO clinical trial show no reports of ocular SAEs or drug-related systemic SAEs. Further, there were no reported adverse events such as vitreous floaters, endophthalmitis, retinal detachment, implant migration in the anterior chamber, retinal vasculitis, or posterior segment inflammation. These data showed 76% and 53% of patients did not require rescue following a single dose of EYP-1901 up to four and six months, stable and sustained BCVA (-2.5 letters) and CST (-2.7 μm), a 79% reduction in treatment burden at six months, and a median time to rescue of six months across all patients.

“We are grateful to the patients, investigators, and site staff who are participating in the DAVIO Phase 1 trial. We are very encouraged by today’s data results, which demonstrated the safety and sustained anti-VEGF activity of EYP-1901 in wet AMD patients,” said David S. Boyer, M.D., a member of EyePoint’s Scientific Advisory Board and a DAVIO Clinical Investigator. “Seeing treatment improvements for these patients is very promising, and we look forward to starting the next phase of this development program next year.”

"Our clinical trial includes patients with previously treated wet AMD, who received frequent anti-VEGF injections prior to entering DAVIO. We were thrilled to see how well tolerated the EYP-1901 inserts appear to be and how well patients responded to EYP-1901 for both vision and anatomical endpoints over the six-month interim report of this 12-month study. These results are not only promising as we plan to move EYP-1901 into Phase 2 in wet AMD, but also for the potential to change the treatment paradigm for many wet AMD patients," said Jay S. Duker, M.D., Chief Operating Officer of EyePoint Pharmaceuticals. "We are encouraged by responses to date and will continue to monitor the progress of these patients as they complete the second half of this trial.”

EyePoint plans to initiate a Phase 2 wet AMD clinical trial in 2022 and the Company has scheduled a Type C meeting with the FDA on December 1, 2021, to discuss specific plans and obtain guidance on potential EYP-1901 registration trials. The Company also expects to initiate additional EYP-1901 clinical trials in diabetic retinopathy (DR) and retinal vein occlusion (RVO).

 

Conference Call and Webcast Information

EyePoint will host a conference call and webcast today at 12:00 p.m. EST or 11:00 a.m. CST. To access the live conference call, please dial (877) 312-7507 (domestic) or (631) 813-4828 (international) and reference conference ID 9396888. A live audio webcast of the event can be accessed via the Investors section of the Company website at www.eyepointpharma.com. A webcast replay will also be available on the corporate website at the conclusion of the call.

 

 

---

 

 

About EYP-1901

EYP-1901 is an investigational agent combining a bioerodible formulation of EyePoint’s proprietary Durasert® sustained release technology with vorolanib, a tyrosine kinase inhibitor. Vorolanib provided efficacy signals in two prior human trials in wet AMD as an orally delivered therapy with no significant ocular adverse events. Interim six-month data from the ongoing Phase 1 DAVIO clinical trial of EYP-1901 show no reports of ocular serious adverse events (SAEs) or drug-related systemic SAEs and efficacy data up to six months in the majority of enrolled patients after a single intravitreal injection. EYP-1901 is initially being developed as a treatment for wet AMD, with the potential for additional indications in DR and RVO.

 

About Wet AMD

AMD impacts as many as 11 million Americans, and up to 15 percent of those patients are impacted by the wet form of AMD, which can lead to blindness. With the current standard of care requiring monthly or bimonthly intravitreal injections, treatment adherence remains an ongoing challenge for patients and physicians.

 

About EyePoint Pharmaceuticals, Inc. 

EyePoint Pharmaceuticals (Nasdaq:EYPT) is a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company's pipeline leverages its proprietary Durasert^® technology for sustained intraocular drug delivery including EYP-1901, a potential twice-yearly intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. The Company has two commercial products: YUTIQ^®, for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU^®, for the treatment of postoperative inflammation following ocular surgery. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts. To learn more about the Company, please visit www.eyepointpharma.com and connect on Twitter and LinkedIn.

 

SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION ACT OF 1995: To the extent any statements made in this press release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding the potential for EYP-1901 as a twice-yearly sustained delivery intravitreal anti-VEGF treatment targeting wet AMD, with potential in DR and RVO; our expectations regarding the timing and outcome of our Phase 1 DAVIO clinical trial for EYP-1901 for the potential treatment of wet AMD; our expectations regarding the timing and clinical development of our product candidates, including EYP-1901 and YUTIQ 50; and the potential advantages of our product candidates for the treatment of eye diseases; and other statements identified by words such as “will,” “potential,” “could,” “can,” “believe,” “intends,” “continue,” “plans,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause EyePoint’s actual results to be materially different than those expressed in or implied by EyePoint’s forward-looking statements. For

 

---

 

EyePoint, this includes uncertainties regarding the timing and clinical development of our product candidates, including EYP-1901; the effectiveness and timeliness of clinical trials, and the usefulness of the data; the timeliness of regulatory approvals; the continued impact of the COVID-19 pandemic on EyePoint’s business, the medical community and the global economy and the impact of general business and economic conditions; the success of current and future license agreements; protection of our intellectual property and avoiding intellectual property infringement; retention of key personnel; manufacturing risks; and other factors described in our filings with the Securities and Exchange Commission. We cannot guarantee that the results and other expectations expressed, anticipated or implied in any forward-looking statement will be realized. A variety of factors, including these risks, could cause our actual results and other expectations to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements. Should known or unknown risks materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected in the forward-looking statements. You should bear this in mind as you consider any forward-looking statements. Our forward-looking statements speak only as of the dates on which they are made. We do not undertake any obligation to publicly update or revise our forward-looking statements even if experience or future changes makes it clear that any projected results expressed or implied in such statements will not be realized.

 

Investors:

Christina Tartaglia
Stern IR
Direct: 212-698-8700
christina.tartaglia@sternir.com

 

Media Contact:

Amy Phillips
Green Room Communications

Direct: 412-327-9499

aphillips@greenroompr.com

 

 

 

1 | EYEPOINT PHARMACEUTICALS Delivering Innovation to the Eye EYP-1901 DAVIO Study Interim Results November 13, 2021 Exhibit 99.2

Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we intend, expect, plan or believe may occur in the future, including but not limited to statements about our expectations regarding the potential benefits of our partnerships and strategic alliances with other companies, as well as the timing and clinical development of our product candidates, including EYP-1901; the potential for EYP-1901 as a vital, novel twice-yearly treatment for wet age-related macular degeneration, diabetic retinopathy and retinal vein occlusion; and our longer term financial and business goals and expectations, are forward-looking statements. Some of the factors that could cause actual results to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements are risks and uncertainties inherent in our business including, without limitation: the effectiveness and timeliness of clinical trials, and the usefulness of the data; the timeliness of regulatory approvals; the extent to which COVID-19 impacts our business; our ability to achieve profitable operations and access to needed capital; fluctuations in our operating results; our ability to successfully produce sufficient commercial quantities of YUTIQ® and DEXYCU® and to successfully commercialize YUTIQ and DEXYCU in the U.S.; our ability to sustain and enhance an effective commercial infrastructure and enter into and maintain commercial agreements for YUTIQ and DEXYCU; the development of our YUTIQ line extension shorter-duration treatment for non-infectious uveitis affecting the posterior segment of the eye; the success of current and future license agreements, including our agreements with Ocumension Therapeutics and Equinox Science; termination or breach of current license agreements, including our agreements with Ocumension Therapeutics and Equinox Science; our dependence on contract research organizations, co-promotion partners, and other outside vendors and service providers; effects of competition and other developments affecting sales of products; market acceptance of products; effects of guidelines, recommendations and studies; protection of intellectual property and avoiding intellectual property infringement; retention of key personnel; product liability; industry consolidation; compliance with environmental laws; manufacturing risks; risks and costs of international business operations; volatility of our stock price; possible dilution; absence of dividends; and other factors described in our filings with the Securities and Exchange Commission. We cannot guarantee that the results and other expectations expressed, anticipated or implied in any forward-looking statement will be realized. A variety of factors, including these risks, could cause our actual results and other expectations to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements. Should known or unknown risks materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected in the forward-looking statements. You should bear this in mind as you consider any forward-looking statements. Our forward-looking statements speak only as of the dates on which they are made. We do not undertake any obligation to publicly update or revise our forward-looking statements even if experience or future changes makes it clear that any projected results expressed or implied in such statements will not be realized. Forward looking statements

COMPANY OVERVIEW Pipeline leveraging proven Durasert® technology * Compelling pipeline focused on retinal disease EYP-1901 - advancing into phase 2 trials for wet AMD, diabetic retinopathy (DR), and retinal vein occlusion (RVO) after positive phase 1 top line results YUTIQ50 – potential six month treatment for posterior uveitis entering phase 3 to support SNDA filing Additional molecules and MOA under evaluation Durasert® - proven intravitreal (IVT) drug delivery platform Sustained local drug delivery Constant (zero-order kinetics), stable release of drug in the eye over weeks, months or years Safely administered to thousands of patients' eyes across four FDA approved products Commercial franchises - YUTIQ® and DEXYCU® 2021 net product revenues improving as COVID-19 restrictions eased across the U.S. 3 | EYEPOINT PHARMACEUTICALS *non-erodible

EYP-1901 - Vorolanib in bioerodible Durasert® Our goal is nothing short of transforming the treatment of wet AMD, diabetic retinopathy, and retinal vein occlusion PIPELINE 4 | EYEPOINT PHARMACEUTICALS

Real world need... today's wet AMD treatments still result in vision loss over time PIPELINE EYP-1901 Adjusted Mean Change From Baseline in VA Letter Score 3 6 12 Month 12 p=0.67† Aflibercept Ranibizumab 1.52 1.01 -0.19 1.24 0.71 -0.30 Follow-up (Month) Lotery et al., Eye (2017) 31, 1697–1706 RETROSPECTIVE STUDY OF 3350 RANIBIZUMAB AND 4300 AFLIBERCEPT TREATMENT-NAIVE EYES WITH WET AMD 4 3 2 1 0 -1 -2 -3 -4 0 5 | EYEPOINT PHARMACEUTICALS

PIPELINE EYP-1901 RETROSPECTIVE STUDY OF 3350 RANIBIZUMAB AND 4300 AFLIBERCEPT TREATMENT-NAIVE EYES WITH WET AMD 6 | EYEPOINT PHARMACEUTICALS Real World Reality – Even One Missed Injection Can Mean Loss of Vision Study evaluated 1,041 pts getting intravitreal anti-VEGF therapies 60% went to scheduled follow up - 40% did not Conclusion: With frequent injections required for current standard of care, a delay in care of only 5.34 weeks resulted in visual loss Sustained release options may give practitioners and patients improved outcomes

EYP-1901 – A Novel Approach to Wet AMD Therapy Vorolanib in Durasert® (bioerodible) 7 Vorolanib Receptor-binding, small molecule tyrosine kinase inhibitor (TKI) Activity against all isoforms of VEGF and PDGF Oral vorolanib previously studied in a wet AMD ph1 and ph2 programs1,2 Strong efficacy signal but systemic toxicity halted the ph2 study No ocular toxicity noted Jackson et al. JAMA Ophthalmol 2017 Cohen MN et al. Br J Ophthalmol. 2021

Bioerodible Durasert® Platform: injectable, sustained-delivery system Similar to YUTIQ®, Retisert®, and Vitrasert® Main difference: No polyimide shell Bioerodible Drug release dynamics Initial burst near the surface of implant Constant, zero-order kinetic release rate for months EYP-1901 – A Novel Approach to Wet AMD Therapy Vorolanib in Bioerodible Durasert® 8 | EYEPOINT PHARMACEUTICALS

23 | EYEPOINT PHARMACEUTICALS Effective blocking of VEGFR Prevents Exudation and Loss of Vision PIPELINE EYP-1901 VEGF-B VEGF-C VEGF-D VEGF-A R1 / INFLAMMATION R2 / BLOOD VESSEL LEAKAGE R3 / BLOOD VESSEL GROWTH & LEAKAGE VEGF SIGNALING PATHWAYS VOROLANIB 9 | EYEPOINT PHARMACEUTICALS Other Anti-VEGF-A therapies VOROLANIB VOROLANIB

EYP-1901 phase 1 trial interim results 10 | EYEPOINT PHARMACEUTICALS

All objectives successfully met Positive safety data: No ocular Serious Adverse Events (SAEs) reported No drug-related systemic SAEs reported All ocular AEs were < grade 2; the only grade 3 AE was not drug-related EFFICACY Positive Efficacy Data: Stable VA and OCT Median time to rescue: 6 months Clinically significant reduction in treatment burden SAFETY 11 | EYEPOINT PHARMACEUTICALS DAVIO: EYP-1901 Durasert and Vorolanib in Ophthalmology Phase 1 Study Interim Data Summary

NO mandated EYP 1901 retreatments Criteria for rescue anti-VEGF therapy*: New fluid > 75 microns (OCT) compared to Day-0 2 lines of BCVA secondary to wet AMD compared to Day-0 New macular hemorrhage secondary to wet AMD *at the discretion of the investigator Enrollment Previously treated wet AMD eyes only No exclusion for presence of fluid Primary endpoint: safety Interim at month-6 Full readout at month-12 Secondary endpoints: BCVA CST as measured by OCT Note: All doses delivered in a single intravitreal injection. BCVA: best corrected visual acuity; OCT: optical coherence tomography; CST: central subfield thickness   Screening visit SOC Injection Low-Mid Dose (1030 ��g) N=1 Low Dose (440 ��g) N=3 RESULTS Month-12 Full Read High Dose (3090 ��g) N=5 Mid Dose (2060 ��g) N=8 RESULTS Month 6 Interim data EYP 1901 7 – 10 days later 12 | EYEPOINT PHARMACEUTICALS DAVIO - Durasert and Vorolanib In Ophthalmology - Wet AMD Phase 1 Trial. Open label, Dose Escalation, No Control Arm

BCVA: best corrected visual acuity; ETDRS: Early Treatment Diabetic Retinopathy Study; CST: central subfield thickness 13 | EYEPOINT PHARMACEUTICALS EYP-1901 Phase 1 DAVIO Participants and Follow-Up

14 | EYEPOINT PHARMACEUTICALS Results: Safety

No other reported significant adverse events such as: No vitreous floaters No endophthalmitis No retinal detachment No implant migration in the anterior chamber No retinal vasculitis No posterior segment inflammation AC, anterior chamber; AE, adverse event; BCVA, best corrected visual acuity; SAE, serious adverse event No ocular serious adverse events (SAEs) reported No drug-related systemic SAEs reported Ocular AEs: One eye: mild asymptomatic anterior chamber cell/flare; Treated with Maxitrol® eyedrops – resolved in 8 days One eye: asymptomatic vitreous hemorrhage from injection; Observed 15 | EYEPOINT PHARMACEUTICALS DAVIO Primary Endpoint – Safety Positive Overall Safety Data

a. All mild-to-moderate in severity and determined not related to study drug b. Grade 1/Mild AEs of particular interest AC anterior chamber; AE, adverse event; BCVA, best corrected visual acuity; OS, left eye; OU; both eyes 16 | EYEPOINT PHARMACEUTICALS DAVIO Summary to Date – Ocular Safety 

17 | EYEPOINT PHARMACEUTICALS Results: Visual acuity, CST, Rescue Free rates, and Reduction in Treatment Burden

Results: Average Visual Acuity (VA) Stable 6 Months After Treatment 18 BCVA: best corrected visual acuity Interim data – monitored through 4 months For all 17 eyes at 6 months VA = -2.5 letters

OCT: optical coherence tomography; CST: central subfield thickness Interim data – monitored through 4 months 19 | EYEPOINT PHARMACEUTICALS Results: Central Subfield Thickness (CST) Sustainable Anatomical Control & Efficacy For all 17 eyes at 6 months CST on OCT = - 2.7 microns

Interim data – monitored through 4 months 20 | EYEPOINT PHARMACEUTICALS Rescue-free Rates up to Each Visit: Entire Study group Median Time to Rescue = 6 Months

Interim data – monitored through 4 months 21 | EYEPOINT PHARMACEUTICALS Rescue-free Rates up to Each Visit Median Time to Rescue = 6 Months 8 of 17 eyes remain rescue-free at 6 months

Details on Patients (n=9) That Received Rescue Anti-VEGF Therapy CST: central subfield thickness; SRF: subretinal fluid; IRF: intra-retinal fluid CST’s NOT Reading Center Confirmed - Interim data – monitored through 4 months

SOC Anti-VEGF Injections Before and After Treatment SoC (Anti-VEGF) + EYP1901 ● Anti-VEGF ○ No rescue injection given ☐ Missed visit months 23 | EYEPOINT PHARMACEUTICALS Results: Clinically Significant Reduction in Treatment Burden 79 % for the entire cohort Interim data – monitored through 4 months

SOC Anti-VEGF Injections Before and After Treatment Results: Clinically Significant Reduction in Treatment Burden of 79 % for the Entire Cohort SoC (Anti-VEGF) + EYP1901 ● Anti-VEGF ○ No rescue injection given ☐ Missed visit months Interim data – monitored through 4 months

Treatment Burden After EYP1901 Substantial and Highly Clinically Relevant Reduction Reduction in Treatment Burden at 6 months post-treatment 100 % reduction = no rescue through 6 months 25 | EYEPOINT PHARMACEUTICALS Treatment Burden After EYP1901 Substantial and Highly Clinically Relevant Reduction Interim data – monitored through 4 months

Screening Visit: 6 anti-VEGF injections prior to enrollment Initial Diagnosis: 9 months prior to enrollment Screening visits prior to treatment 26 | EYEPOINT PHARMACEUTICALS Case 1: Entered Dry, Stayed Dry for 9 Months Low dose cohort (EYP-1901 440 µg)

Month 5 – no rescue 27 | EYEPOINT PHARMACEUTICALS Case 1: Post-Treatment (No Rescues Through Month 9) Low dose cohort (EYP-1901 440 µg)

Screening Visit (9 prior anti-VEGF injections) Prior to Treatment 28 | EYEPOINT PHARMACEUTICALS Case 2: Rescued at Month 1 Failure of Both SOC therapy and EYP 1901 Low dose cohort (EYP-1901 440 µg) Significant intraretinal fluid

Case 2: 9 anti-VEGF injections prior to screening Low Dose Cohort (EYP-1901 440 µg) Despite early rescue, EYP1901 still reduced treatment burden by 34% Month 1 – Rescue 8 weeks post Eylea #1 12 weeks post EYP1901 5 weeks post Eylea 4 weeks post EYP1901 4 weeks post Eylea 16 weeks post EYP1901 8 weeks post Eylea 20 weeks post EYP1901 4 weeks post Eylea 24 weeks post EYP1901 29 4 weeks post Eylea rescue # 3 24 weeks post EYP1901 5 weeks post Eylea rescue # 3 24 weeks post EYP1901

30 | EYEPOINT PHARMACEUTICALS Screening Visit (8 prior anti-VEGF injections) Prior to treatment Case 3: Entered the Study With Subretinal Fluid High dose cohort (EYP-1901 3090 µg)

31 | EYEPOINT PHARMACEUTICALS Case 3: Post-treatment – New Fluid Doesn’t Mean Rescue ! High dose cohort (EYP-1901 3090 µg)

All objectives successfully met: Proof of Concept for Vorolanib in wet AMD Positive Safety Data No ocular SAEs reported No drug-related systemic SAEs reported Ocular AEs - majority mild and to be expected EFFICACY Positive Efficacy Data: Stable VA and OCT Median time to rescue: 6 months 76 % rescue-free up to 4 months 53 % rescue-free up to 6 months Clinically significant reduction in treatment burden by 79 % SAFETY 32 | EYEPOINT PHARMACEUTICALS DAVIO Summary: EYP-1901 Phase 1 Clinical Trial Met All Objectives DURABILITY 8 of 17 (47 %) eyes still rescue-free One eye out nine months rescue-free

Key Takeaways for EYP-1901 from DAVIO Study 33 | EYEPOINT PHARMACEUTICALS EYP-1901 (vorolanib delivered with our bioerodible DURASERT) - favorable safety and tolerability profile Proof of Concept - clinically significant activity of vorolanib in wet AMD setting Demonstrated ability of DURASERT technology to deliver controllable, extended release of active drug over months Implies highly clinically significant improvements to dosing frequency relative to SoC PIPELINE EYP-1901 Summary of Clinical Findings

Key Takeaways for EYP-1901 from DAVIO Study 34 | EYEPOINT PHARMACEUTICALS Advance EYP-1901 into three Phase 2 clinical trials by YE:2023 Wet AMD initiation expected in 2022, Diabetic Retinopathy initiation expected in 2022, and Retinal Vein Occlusion initiation expected by 2023 FDA Type C meeting in December 2021 to further inform wet AMD clinical development plan Use clinical findings and observations around biomarkers to refine Phase 2 clinical trial design in wet AMD PIPELINE EYP-1901 Next Steps for EYP-1901

35 | EYEPOINT PHARMACEUTICALS Refine Phase 2 Trial - Post-Hoc Analysis of OCT Biomarkers – Wet AMD eyes with intraretinal fluid (IRF) - poor prognosis DAVIO enrolled four subjects with foveal IRF at Screening

36 | EYEPOINT PHARMACEUTICALS Post-hoc Analysis of Rescue-Free Rates for Eyes with No Foveal Intraretinal Fluid (IRF) - N=13 Rescue-free rate up to each visit for eyes w no IRF Interim data – monitored through 4 months

SoC (Anti-VEGF) + EYP1901 months ● Anti-VEGF ○ No rescue injection given ☐ Missed visit 37 | EYEPOINT PHARMACEUTICALS Post-hoc Results: 91% reduction in treatment burden Excluding four patients with foveal intraretinal fluid at Screening SOC Anti-VEGF Injections Before and After Treatment Interim data – monitored through 4 months

EyePoint 2022+ — Positioned to Transform the Ophthalmology Landscape 38 | EYEPOINT PHARMACEUTICALS Paradigm-shifting potential of DURASERT technology now demonstrated with multiple approved drugs and small molecule agents Ability to harness technology for small molecule agents with different MOAs Ability to tailor and control dosing frequency for specific indications and patient populations Ability to inject multiple implants simultaneously Focus on executing multiple clinical POC studies for EYP-1901 Apply new technological enhancements to DURASERT platform to further expand the scope and scale of new indications PIPELINE EYP-1901

SOC Anti-VEGF Injections Before and After Treatment SoC (Anti-VEGF) + EYP1901 ● Anti-VEGF ○ No rescue injection given ☐ Missed visit months 39 | EYEPOINT PHARMACEUTICALS Most Compelling Data from DAVIO - Clinically Significant Reduction in Treatment Burden of 79 % for the entire cohort Interim data – monitored through 4 months

1 | EYEPOINT PHARMACEUTICALS Delivering Innovation to the Eye